NMRA
$2.85-0.02 (-0.70%)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...
Recent News
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity
Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the 11 most popular AI penny stocks to buy now. On February 17, Myles Minter from William Blair upgraded his rating on Neumora Therapeutics Inc. (NASDAQ:NMRA) from Market Perform to Outperform. The analyst also shared a net present value figure of $7.62 per share for the stock’s valuation. […]
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511
Neumora Therapeutics Inc (NASDAQ:NMRA) is among the best NASDAQ penny stocks to buy according to analysts. Presenting at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, Neumora executives shared additional data from the Phase 1b study of drug candidate NMRA-511. Neumora is developing NMRA-511 as a treatment for agitation in Alzheimer’s disease patients. […]
Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026
Neumora Therapeutics (NASDAQ:NMRA) executives highlighted new clinical-scale analyses for NMRA-511 in Alzheimer’s disease (AD) agitation and reviewed pipeline milestones during a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026. NMRA-511: Additional Phase 1b analyses in AD agitat
3 Promising Penny Stocks With Market Caps Up To $400M
The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different market segments. While penny stocks might seem like a throwback to earlier trading days, they continue to offer intriguing possibilities for those interested in smaller or emerging companies with potential growth prospects.
How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine
Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.